Treatment of Porocarcinoma With Mohs Micrographic Surgery:... : Dermatologic Surgery (original) (raw)

Original Article

The Mayo Clinic Experience

Tolkachjov, Stanislav N. MD; Hocker, Thomas L. MD; Camilleri, Michael J. MD; Baum, Christian L. MD

*Department of Dermatology, Mayo Clinic, Rochester, Minnesota;

†Advanced Dermatologic Surgery, Overland Park, Kansas;

‡Division of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota;

§Division of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota

Address correspondence and reprint requests to: Stanislav N. Tolkachjov, MD, 200 First Street SW, Rochester, MN 55905, or e-mail: [email protected]

The authors have indicated no significant interest with commercial supporters.

Abstract

BACKGROUND

Eccrine porocarcinoma (EPC) is a rare malignant adnexal neoplasm with reported metastatic potential and undefined optimal treatment.

OBJECTIVE

This study reviews the clinical characteristics and outcomes of patients with EPC treated with Mohs micrographic surgery (MMS).

MATERIALS AND METHODS

The authors performed a retrospective chart review of patients with EPC treated by MMS at the Mayo Clinic from 1995 to 2013, recording patient demographics, tumor characteristics, MMS stages to clearance, follow-up, recurrence, metastasis, and mortality.

RESULTS

A total of 9 patients underwent MMS for EPC in 19 years. The average age was 64.2 years, with 6 males and 3 females. All patients were Caucasian. The head and lower extremity were the most common locations (44% each), with 1 on the forearm. Of the 9 tumors, 8 were located on the right side of the body. The mean preoperative tumor size and postoperative defect were 2.9 and 7.8 cm2, respectively, when 2 outliers were excluded. An average of 1.3 MMS stages was required for clearance. The mean postoperative follow-up was 3.3 years (range: 1–60 months). No tumors treated with MMS recurred, metastasized, or led to disease-related mortality.

CONCLUSION

Mohs micrographic surgery seems to be a useful treatment modality for EPC. This is one of the largest single-center series of EPC treated with MMS.